Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
14 p, 572.1 KB Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer / Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ; Navarro, Alejandro (VHIO) ; Carbonell, Caterina (VHIO) ; Callejo, Anna (VHIO) ; Iranzo, Patricia (VHIO) ; Cedrés, Susana (VHIO) ; Martinez-Martí, Alex (VHIO) ; Pardo, Nuria (VHIO) ; Saoudi-Gonzalez, Nadia (VHIO) ; Martinez, D. (Translational Genomics and Targeted Therapies in Solid Tumors. IDIBAPS) ; Jiménez, José (VHIO) ; Sansano, Irene (Hospital Universitari Vall d'Hebron) ; Mancuso, Francesco M. (VHIO) ; Nuciforo, Paolo (VHIO) ; Montuenga, L.M. (Navarra Health Research Institute (IDISNA)) ; Sánchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Prat, A. (Translational Genomics and Targeted Therapies in Solid Tumors. IDIBAPS) ; Vivancos, Ana (VHIO) ; Felip, Enriqueta (VHIO) ; Amat, Ramón (VHIO) ; Universitat Autònoma de Barcelona
Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. [...]
2020 - 10.1002/1878-0261.12891
Molecular Oncology, 2020  
2.
13 p, 3.4 MB Network-based proteomic approaches reveal the neurodegenerative, neuroprotective and pain-related mechanisms involved after retrograde axonal damage / Casas Louzao, Caty (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Isus, Laura (Institut de Recerca Biomèdica de Lleida) ; Herrando-Grabulosa, Mireia (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ; Borrás, Eva (Universitat Pompeu Fabra. Centre de Regulació Genòmica) ; Sabidó, Eduardo (Universitat Pompeu Fabra. Centre de Regulació Genòmica) ; Forés Vineta, Joaquim (Hospital Clínic i Provincial de Barcelona) ; Aloy, Patrick (Institució Catalana de Recerca i Estudis Avançats (ICREA))
Neurodegenerative processes are preceded by neuronal dysfunction and synaptic disconnection. Disconnection between spinal motoneuron (MN) soma and synaptic target leads either to a retrograde degenerative process or to a regenerative reaction, depending injury proximity among other factors. [...]
2015 - 10.1038/srep09185
Scientific reports (Nature Publishing Group), Vol. 5 (2015) , art. 9185  
3.
8 p, 473.7 KB RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer / Cruz, C. (Vall d'Hebron Institut d'Oncologia) ; Castroviejo-Bermejo, M. (Experimental Therapeutics Group) ; Gutiérrez-Enríquez, S. (Oncogenetics Group) ; Llop-Guevara, A. (Experimental Therapeutics Group) ; Ibrahim, Y.H. (Experimental Therapeutics Group) ; Gris-Oliver, Albert. (Experimental Therapeutics Group) ; Bonache, S. (Oncogenetics Group) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Bruna, A. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Rueda, O.M. (Cancer Research UK Cambridge Institute. University of Cambridge) ; Lai, Z. (AstraZeneca (USA)) ; Polanska, U.M. (Cancer Research UK. Cambridge Institute) ; Jones, G.N. (Cancer Research UK. Cambridge Institute) ; Kristel, P. (The Netherlands Cancer Institute (NKI) (Netherlands)) ; de Bustos, L. (Experimental Therapeutics Group) ; Guzman, M. (Experimental Therapeutics Group) ; Rodríguez, O. (Experimental Therapeutics Group) ; Grueso, J. (Experimental Therapeutics Group) ; Montalban, G. (Oncogenetics Group) ; Caratú, G. (Cancer Genomics Group) ; Mancuso, F. (Cancer Genomics Group) ; Fasani, R. (Vall d'Hebron Institut d'Oncologia) ; Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ; Howat, W.J. (Cancer Research UK. Cambridge Institute) ; Dougherty, B. (AstraZeneca (USA)) ; Vivancos, A. (Cancer Genomics Group) ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Serres-Créixams, X. (Department of Radiology) ; Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ; Oaknin, A. (Vall d'Hebron Institut d'Oncologia) ; Cadogan, E. (Cancer Research UK. Cambridge Institute) ; Barrett, J.C. (AstraZeneca (USA)) ; Caldas, C. (Cambridge University. NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre (UK)) ; Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center (USA)) ; Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ; Cortes, Javier (Vall d'Hebron Institut d'Oncologia) ; Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Jonkers, J. (Cancer Genomics Group) ; Diez, Orland (Hospital Universitari Vall d'Hebron) ; O'Connor, M.J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210  

Vea también: autores con nombres similares
1 Mancuso, F.M.
1 Mancuso, Francesco
2 Mancuso, Francesco M.
1 Mancuso, Francesco Mattia
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.